Table 2.
Comparison between Quality Effect Model and the Random Effect Model results
| Quality effect model | Random effect model | ||||||
|---|---|---|---|---|---|---|---|
| No. of studies (patients) | Prevalence (CI 95%) | I2% | No. of studies (patients) | Prevalence (CI 95%) | I2% | ||
| All eligible studies | 14 (917) | 20% (7–36%) | 94.6% | 14 (917) | 63% (17–44%) | 94.6% | |
| Risk of Bias | |||||||
| Low ROB | 6 (604) | 11% (1–27%) | 94.7% | 6 (604) | 66% (4–31%) | 94.7% | |
| Moderate ROB | 8 (313) | 40% (21–60%) | 87.1% | 2 (313) | 63% (26–59%) | 87.1% | |
| Studies with good external validity | 3 (374) | 5% (0–14%) | 85.5% | 3 (374) | 49% (1–16%) | 85.5% | |
| Gene mutations | |||||||
| Both BRCA1 and BRCA2 | 7 (477) | 34% (18–52%) | 93.2% | 7 (477) | 78% (22–56%) | 93.2% | |
| BRCA1 | 11 (684) | 19% (7–36%) | 92.8% | 11 (684) | 59% (15–42%) | 92.8% | |
| BRCA2 | 6 (488) | 27% (16–40%) | 87.4% | 6 (488) | 75% (18–42%) | 87.4% | |
| Target population | |||||||
| HBOC | 3 (348) | 7% (0–20%) | 91.8% | 3 (348) | 55% (0–25%) | 91.8% | |
| HBC | 11 (569) | 32% (18–47%) | 90.8% | 10 (550) | 65% (23–50%) | 90.8% | |
| HOC | 1 (192) | 2% (0–5%) | 0 | 1 (192) | 33% (0–5%) | 0 | |
| Geographic Location | |||||||
| Levant | 4 (240) | 28% (11–49%) | 87.9% | 4 (240) | 63% (13–49%) | 87.9% | |
| GCC | 2 (142) | 22% (0–58%) | 93.9% | 2 (142) | 24% (0–56%) | 93.9% | |
| North Africa | 8 (535) | 16% (0–43%) | 96.2% | 8 (535) | 64% (11–54%) | 96.2% | |
| Sample size | |||||||
| < 100 | 12 (603) | 29% (16–44%) | 89.9% | 12 (603) | 62% (21–48%) | 89.9% | |
| ≥100 | 2 (314) | 5% (0–16%) | 91.4% | 2 (314) | 52% (0–17%) | 91.4% | |
| Year of recruitment | |||||||
| ≤2011 | 10 (467) | 25% (8–47%) | 93.1% | 10 (467) | 60% (17–52%) | 93.1% | |
| 2012–2018 | 5 (572) | 13% (1–31%) | 95.6% | 5 (572) | 71% (5–37%) | 95.6% | |
| Type of mutation | |||||||
| Deleterious | 8 (532) | 26% (11–44%) | 93.6% | 8 (532) | 71% (17–49%) | 93.6% | |
| Deleterious and VUS | 2 (266) | 10% (0–100%) | 98.8% | 2 (266) | 73% (0–85%) | 98.8% | |
| Deleterious, VUS, and Polymorphisims | 4 (119) | 20% (4–43%) | 72.4% | 4 (119) | 46% (7–57%) | 85.0% | |